Table 1 Patient characteristics
From: Interfractional target changes in brain metastases during 13-fraction stereotactic radiotherapy
Age | Median, 70 years (range 42–85 years) |
|---|---|
Sex (male/female) | 19/4 |
Karnofsky Performance Status | Median, 90 (range 50–100) |
Primary tumor (number of brain metastases) | |
Lung cancer | 15 (19) |
Renal cell carcinoma | 3 (3) |
Others | 5 (5) |
Prior whole-brain radiotherapy | 2 cases (25 Gy/10 fr., 30 Gy/10 fr.) |
Cystic component or necrosis (yes/no) | 19/8 |
Treatment device per lesion | |
TrueBeamSTx/Vero4DRT | 25/2 |
Prescribed dose | |
Prescribed to isocenter | 4 lesions with 48.75 Gy/13 fr. (PTV was almost covered by 80% isodose line of the prescribed dose) |
D99.5% = 100% | 23 lesions with 39–42 Gy/13 fr. (Dmax: almost 125% of the prescribed dose) |